Moleculin Biotech, Inc. — Director's Dealing 2022

Nov 23, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2022-11-21

Reporting Person: KLEMP WALTER V (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-21	Common Stock	P	22500	$1.1496	Acquired	364890	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $1.12 to $1.17. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.